Pancreatic cancer hENT1 expression and survival from Gemcitabine in patients from the ESPAC-3 trial.

Greenhalf, W; Ghaneh, P; Neoptolemos, J; Palmer, D; Cox, T; Lamb, R; Garner, E; Campbell, F; Mackey, J; Costello, E; Moore, M; Valle, Juan W; McDonald, A; Carter, R; Tebbutt, N; Goldstein, D; Shannon, J; Dervenis, C; Glimelius, B; Deakin, M; Charnley, R; Lacaine, F; Scarfe, A; Middleton, M; Anthoney, A; Halloran, C; Mayerle, J; Oláh, A; Jackson, R; Rawcliffe, C; Scarpa, A; Bassi, C; Büchler, M

Abstract

Human equilibrative nucleoside transporter 1 (hENT1) levels in pancreatic adenocarcinoma may predict survival in patients who receive adjuvant gemcitabine after resection.

Citation

Pancreatic cancer hENT1 expression and survival from Gemcitabine in patients from the ESPAC-3 trial. 2013: J Natl Cancer Inst

Journal

Journal of the National Cancer Institute

URI

http://hdl.handle.net/10541/308818

DOI

10.1093/jnci/djt347

PubMed ID

24301456

Type

Article

Language

ISSN

1460-2105

Collections

All Christie Publications

Pancreatic cancer hENT1 expression and survival from Gemcitabine in patients from the ESPAC-3 trial.

Authors

Issue Date

Metadata